• David Zweiker, Christian Koppelstätter, Katharina Hohenstein, Irene Lang, Sabine Perl, Heiko Bugger, Mathias-Christoph Brandt, Sabine Horn, Ronald K Binder, Bruno Watschinger, Matthias Frick, Alexander Niessner, and Thomas Weber.
• Third Medical Department for Cardiology and Intensive Care, Vienna Healthcare Group, Clinic Ottakring, Montleartstraße 36, Pavillon 29, 1160, Vienna, Austria. davidzweiker@gmail.com.
• Wien. Klin. Wochenschr. 2024 Sep 1; 136 (Suppl 14): 559569559-569.

AbstractRenal sympathetic denervation (RDN) is an interventional supplement to medical treatment in patients with arterial hypertension. While the first sham-controlled trial, SYMPLICITY HTN‑3 was neutral, with improved procedural details, patient selection and follow-up, recent randomized sham-controlled trials of second-generation devices show a consistent blood pressure lowering effect of RDN, as compared to sham controls. These new data and the recent U.S. Food and Drug Administration (FDA) premarket approval of two RDN devices are the basis for the present recommendations update.This joint position paper from the Austrian Society of Hypertension, together with the Austrian Society of Nephrology and the Working Group of Interventional Cardiology from the Austrian Society of Cardiology includes an overview about the available evidence on RDN and gives specific recommendations for the work-up, patient selection, pretreatment, procedural management and follow-up in patients undergoing RDN in Austria. Specifically, RDN may be used in clinical routine care, together with lifestyle measures and antihypertensive drugs, in patients with resistant hypertension (i.e. uncontrolled blood pressure on 3 antihypertensive drugs) and in those with uncontrolled hypertension, after adequate work-up, if institutional, patient-related and procedural conditions are fulfilled.© 2024. The Author(s).

23 keywords...

hide…